Northland Securities Maintains a Buy Rating on Verrica Pharmaceuticals (VRCA)

Northland Securities analyst Tim Chiang maintained a Buy rating on Verrica Pharmaceuticals (VRCAResearch Report) today and set a price target of $21.00. The company’s shares closed last Monday at $14.07.

According to TipRanks.com, Chiang is a 2-star analyst with an average return of 0.4% and a 48.7% success rate. Chiang covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, Pacira Pharmaceuticals, and Menlo Therapeutics.

Verrica Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $19.00, which is a 30.9% upside from current levels. In a report released today, Needham also maintained a Buy rating on the stock with a $17.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $18.67 and a one-year low of $6.79. Currently, Verrica Pharmaceuticals has an average volume of 56.87K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Verrica Pharmaceuticals, Inc. operates as a clinical-stage medical dermatology company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its lead product VP-102, is a proprietary topical therapy used in common skin indications including Molluscum contagiosum and Verruca Vulgaris. The company was founded by Matthew Davidson on July 3, 2013 and is headquartered in West Chester, PA.